aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Genmab A/S, founded in February 1999 by Florian Schönharting and Lisa Drakeman, is a Danish biotechnology company headquartered in Copenhagen, Denmark. The company operates internationally with subsidiaries in the Netherlands, USA, and Japan. Genmab's core mission is to improve the lives of patients through innovative antibody therapeutics. The company focuses on developing and commercializing differentiated antibody products for the treatment of cancer and other serious diseases, leveraging its proprietary antibody technologies.
Notable figures affiliated with Genmab include its founders and key investors from BankInvest Biomedical venture fund. Genmab has achieved significant milestones, including dual listings on the Copenhagen Stock Exchange and NASDAQ Global Select Market. The company has made substantial impacts in the biotech industry, particularly with its successful development and commercialization of therapeutic antibodies. Its contributions have advanced cancer treatment options and improved patient outcomes globally.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Biotech
Model Types
Licensing, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Genmab founded?
Genmab was founded in 1999.
Where is Genmab’s headquarters located?
Genmab’s headquarters is located in Copenhagen, 84, DK.
How many employees does Genmab have?
Genmab has 2015 employees as of Feb 12, 2024.
How much has Genmab raised to-date?
As of July 05, 2023, Genmab has raised a total of $204.3M (USD) since Jul 17, 2019.
Add Comparison
Total Raised to Date
$204.3M
USD
Last Update Jul 17, 2019
Total Employees Over Time
2015
As of Feb 2024
Genmab Address
Copenhagen,
Capital Region of Denmark
Denmark
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts